Abstract
Cefiderocol, a novel siderophore cephalosporin in late-stage clinical development, utilizes a “Trojan horse” active transport mechanism to enter bacteria and has proven in vitro activity against carbapenem-resistant gram-negative pathogens, including those with major carbapenem-resistance mechanisms, and stability against all carbapenemases.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Paper Title
Journal
Date
